Takeda Pharmaceutical (TAK) Financials

$14.68 +0.11 (+0.75%)

Closing price 05/27/2025 03:59 PM Eastern

Extended Trading

$14.66 -0.02 (-0.14%)

As of 05/27/2025 05:21 PM Eastern

Annual Income Statements for Takeda Pharmaceutical

This table shows Takeda Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017
Net Income / (Loss) Attributable to Common Shareholders	953	2,388	1,894	3,399	413	1,214	1,758	1,032
Consolidated Net Income / (Loss)	954	2,388	1,895	3,401	413	1,213	1,757	1,037
Net Income / (Loss) Continuing Operations	954	2,388	1,895	3,401	413	1,213	1,757	1,037
Total Pre-Tax Income	349	2,826	2,492	3,311	-567	1,146	2,044	1,287
Total Operating Income	1,416	3,695	3,795	4,604	937	2,135	2,275	1,399
Total Gross Profit	18,761	20,967	20,275	19,919	20,543	12,982	11,992	10,534
Total Revenue	28,196	30,339	29,389	28,908	30,712	18,835	16,658	15,550
Operating Revenue	28,196	30,339	29,389	28,908	30,712	18,835	16,658	15,550
Total Cost of Revenue	9,434	9,372	9,114	8,988	10,169	5,853	4,666	5,016
Operating Cost of Revenue	9,434	9,372	9,114	8,988	10,169	5,853	4,666	5,016
Total Operating Expenses	17,346	17,272	16,480	15,316	19,606	10,847	9,717	9,134
Selling, General & Admin Expense	6,969	7,513	7,299	7,916	9,002	6,445	5,910	5,558
Marketing Expense	4,312	4,086	3,894	3,814	4,250	1,604	1,149	1,407
Research & Development Expense	4,827	4,771	4,332	4,121	4,595	3,308	3,062	2,804
Other Operating Expenses / (Income)	-128	-192	-355	-2,875	-562	-1,436	-1,594	-1,289
Impairment Charge	1,366	1,094	1,310	2,340	2,321	926	1,191	654
Total Other Income / (Expense), net	-1,067	-869	-1,303	-1,293	-1,504	-989	-231	-112
Interest Expense	1,454	1,278	1,372	2,248	1,540	748	300	209
Interest & Investment Income	344	474	195	954	260	151	372	110
Other Income / (Expense), net	43	-65	-127	0.69	-224	-392	-303	-14
Income Tax Expense	-604	437	596	-90	-980	-67	287	250
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.86	-0.16	-0.88	-1.50	-0.46	1.01	1.67	-5.14
Basic Earnings per Share	$0.61	$1.54	$1.21	$240.72	$28.41	$140.61	$239.35	$147.15
Weighted Average Basic Shares Outstanding	1.69B	1.69B	1.67B	1.72B	1.56B	1.57B	-	-
Diluted Earnings per Share	$0.60	$1.52	$1.20	$238.96	$28.25	$139.82	$237.56	$146.26
Weighted Average Diluted Shares Outstanding	1.69B	1.69B	1.67B	1.72B	1.56B	1.57B	-	-
Weighted Average Basic & Diluted Shares Outstanding	1.69B	1.69B	1.67B	1.72B	1.56B	1.57B	-	-

No quarterly income statements for Takeda Pharmaceutical are available.

This table details how cash moves in and out of Takeda Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017
Net Change in Cash & Equivalents	-674	-2,554	-1,196	2,858	-404	3,943	-392	-938
Net Cash From Operating Activities	4,737	7,361	9,248	9,139	6,250	-2,950	3,555	2,346
Net Cash From Continuing Operating Activities	4,832	7,412	9,313	11,218	6,182	2,950	3,555	2,346
Net Income / (Loss) Continuing Operations	954	2,388	1,895	3,401	413	1,213	1,757	1,037
Consolidated Net Income / (Loss)	954	2,388	1,895	3,401	413	1,213	1,757	1,037
Depreciation Expense	4,814	5,005	4,802	5,059	5,446	2,225	1,714	1,539
Non-Cash Adjustments To Reconcile Net Income	2,143	1,842	2,023	1,837	2,325	-36	44	-241
Changes in Operating Assets and Liabilities, net	-3,079	-1,823	593	922	-2,003	-451	41	11
Net Cash From Investing Activities	-3,067	-4,573	-1,631	3,557	2,726	-25,467	-878	-5,887
Net Cash From Continuing Investing Activities	-2,847	-4,573	-1,631	3,557	2,726	-25,465	-878	-5,887
Purchase of Property, Plant & Equipment	-3,179	-4,774	-1,532	-2,138	-2,032	-1,204	-1,207	-1,006
Acquisitions	0.00	0.00	-409	0.00	-46	-26,572	-267	-5,289
Purchase of Investments	-45	-76	-69	-114	-70	-154	-834	-109
Sale of Property, Plant & Equipment	57	7.25	15	420	117	455	28	24
Divestitures	132	60	232	4,795	4,307	765	800	578
Sale and/or Maturity of Investments	214	233	191	688	581	665	478	98
Other Investing Activities, net	-26	-23	-60	-93	-132	577	122	-183
Net Cash From Financing Activities	-2,344	-5,342	-8,813	-9,839	-9,380	26,460	-3,069	2,603
Net Cash From Continuing Financing Activities	-2,741	-5,342	-8,813	-9,839	-9,380	26,460	-3,069	2,603
Repayment of Debt	-3,147	-3,530	-7,889	-17,604	-11,286	2,794	-5,221	-1,820
Repurchase of Common Equity	-15	-203	-638	-334	-35	0.00	-176	-208
Payment of Dividends	-1,899	-2,105	-2,336	-2,562	-2,637	-1,284	-1,335	-1,272
Issuance of Debt	2,493	565	2,053	10,663	4,630	25,110	3,702	5,990
Other Financing Activities, net	-173	-69	-3.17	-1.55	-52	-150	-38	-88

No quarterly cash flow statements for Takeda Pharmaceutical are available.

This table presents Takeda Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018
Total Assets	99,913	105,143	108,515	116,726	119,640	123,873	38,636
Total Current Assets	16,920	18,064	21,357	24,524	23,044	26,880	10,150
Cash & Equivalents	3,027	4,019	6,997	8,735	5,950	6,305	2,771
Accounts Receivable	4,420	4,892	5,737	7,079	7,064	6,663	3,954
Inventories, net	8,062	7,546	7,025	7,002	8,556	12,653	2,041
Current Deferred & Refundable Income Taxes	193	243	228	268	260	65	80
Other Current Assets	1,217	1,364	1,370	1,441	1,213	1,194	1,304
Plant, Property, & Equipment, net	13,158	12,740	13,034	13,143	12,937	11,962	5,051
Plant, Property & Equipment, gross	13,158	12,740	13,034	13,143	12,937	11,962	5,051
Total Noncurrent Assets	69,835	74,339	74,124	79,058	83,660	85,030	23,435
Long-Term Investments	2,848	2,854	2,718	3,149	1,002	972	1,016
Goodwill	35,776	36,088	36,296	36,466	37,443	38,082	9,684
Intangible Assets	28,268	32,163	31,444	35,338	38,925	42,670	9,543
Noncurrent Deferred & Refundable Income Taxes	2,605	2,757	2,985	3,198	2,875	799	611
Other Noncurrent Operating Assets	339	477	680	907	3,415	2,508	2,582
Total Liabilities & Shareholders' Equity	99,913	105,143	108,515	116,726	119,640	123,873	38,636
Total Liabilities	51,811	57,274	61,714	69,924	75,526	77,297	19,655
Total Current Liabilities	15,296	18,696	17,669	16,029	20,304	22,929	6,939
Short-Term Debt	2,429	2,558	1,680	200	5,476	8,846	0.17
Accounts Payable	3,621	4,891	4,251	3,108	2,975	2,940	2,260
Current Deferred & Payable Income Tax Liabilities	727	1,750	1,654	1,313	1,705	1,353	637
Other Current Liabilities	8,520	9,497	10,083	11,408	9,255	9,365	3,763
Total Noncurrent Liabilities	36,514	38,577	44,044	53,895	55,221	54,368	12,716
Long-Term Debt	29,603	30,454	34,103	41,703	42,052	42,803	9,274
Noncurrent Deferred & Payable Income Tax Liabilities	781	2,224	3,896	5,212	7,139	7,035	854
Noncurrent Employee Benefit Liabilities	951	961	1,201	1,436	1,461	1,406	824
Other Noncurrent Operating Liabilities	5,179	4,939	4,845	5,544	4,568	3,124	1,765
Total Equity & Noncontrolling Interests	48,102	47,869	46,801	46,801	44,115	46,575	18,981
Total Preferred & Common Equity	48,097	47,865	46,797	46,764	44,077	46,539	18,793
Preferred Stock	11,555	13,023	14,072	15,263	15,680	14,821	854
Total Common Equity	36,542	34,842	32,725	31,500	28,398	31,719	17,939
Common Stock	11,087	12,628	13,803	15,080	15,566	14,761	733
Retained Earnings	9,200	11,609	12,185	13,649	12,784	14,329	14,652
Treasury Stock	-339	-756	-955	-538	-816	-513	-700
Other Equity Adjustments	16,594	11,361	7,692	3,310	864	3,142	3,299
Noncontrolling Interest	4.90	4.14	4.15	37	37	36	188

No quarterly balance sheets for Takeda Pharmaceutical are available.

This table displays calculated financial ratios and metrics derived from Takeda Pharmaceutical's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	-7.06%	3.23%	1.66%	-5.87%	63.06%	13.07%	7.13%	0.00%
EBITDA Growth	-27.36%	1.94%	-12.35%	56.89%	55.25%	7.65%	26.02%	0.00%
EBIT Growth	-59.82%	-1.05%	-20.33%	545.67%	-59.08%	-11.62%	42.33%	0.00%
NOPAT Growth	23.81%	8.19%	-38.95%	620.97%	-70.97%	15.55%	73.41%	0.00%
Net Income Growth	-60.07%	26.01%	-44.26%	722.79%	-65.93%	-30.94%	69.39%	0.00%
EPS Growth	-60.37%	26.64%	-99.50%	745.88%	-79.80%	-41.14%	62.42%	0.00%
Operating Cash Flow Growth	-35.64%	-20.41%	1.20%	46.22%	311.85%	-182.98%	51.51%	0.00%
Free Cash Flow Firm Growth	82.42%	-71.01%	-49.31%	109.43%	110.01%	-182.41%	0.00%	0.00%
Invested Capital Growth	0.34%	1.56%	-5.15%	-10.24%	-6.33%	269.23%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	66.54%	69.11%	68.99%	68.91%	66.89%	68.92%	71.99%	67.74%
EBITDA Margin	22.25%	28.46%	28.82%	33.43%	20.06%	21.06%	22.12%	18.81%
Operating Margin	5.02%	12.18%	12.91%	15.93%	3.05%	11.33%	13.66%	9.00%
EBIT Margin	5.17%	11.96%	12.48%	15.93%	2.32%	9.25%	11.84%	8.91%
Profit (Net Income) Margin	3.38%	7.87%	6.45%	11.76%	1.35%	6.44%	10.55%	6.67%
Tax Burden Percent	273.15%	84.52%	76.07%	102.71%	-72.90%	105.85%	85.96%	80.58%
Interest Burden Percent	23.94%	77.84%	67.92%	71.90%	-79.50%	65.76%	103.63%	92.89%
Effective Tax Rate	-173.15%	15.48%	23.93%	-2.71%	0.00%	-5.85%	14.04%	19.42%
Return on Invested Capital (ROIC)	5.22%	4.25%	3.86%	5.82%	0.74%	3.89%	15.80%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-5.93%	1.44%	0.32%	2.11%	0.18%	-0.25%	8.91%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-3.23%	0.79%	0.19%	1.66%	0.17%	-0.19%	2.71%	0.00%
Return on Equity (ROE)	1.99%	5.05%	4.05%	7.48%	0.91%	3.70%	18.51%	0.00%
Cash Return on Invested Capital (CROIC)	4.88%	2.70%	9.14%	16.62%	7.28%	-110.86%	-184.20%	0.00%
Operating Return on Assets (OROA)	1.42%	3.40%	3.26%	3.90%	0.59%	2.14%	5.10%	0.00%
Return on Assets (ROA)	0.93%	2.24%	1.68%	2.88%	0.34%	1.49%	4.55%	0.00%
Return on Common Equity (ROCE)	1.48%	3.60%	2.78%	4.93%	0.60%	2.80%	17.49%	0.00%
Return on Equity Simple (ROE_SIMPLE)	1.98%	4.99%	4.05%	7.27%	0.94%	2.61%	9.35%	0.00%
Net Operating Profit after Tax (NOPAT)	3,867	3,123	2,887	4,729	656	2,260	1,955	1,128
NOPAT Margin	13.71%	10.29%	9.82%	16.36%	2.14%	12.00%	11.74%	7.25%
Net Nonoperating Expense Percent (NNEP)	11.14%	2.82%	3.54%	3.72%	0.56%	4.14%	6.90%	0.00%
Cost of Revenue to Revenue	33.46%	30.89%	31.01%	31.09%	33.11%	31.08%	28.01%	32.26%
SG&A Expenses to Revenue	24.72%	24.76%	24.84%	27.38%	29.31%	34.22%	35.48%	35.74%
R&D to Revenue	17.12%	15.73%	14.74%	14.25%	14.96%	17.56%	18.38%	18.03%
Operating Expenses to Revenue	61.52%	56.93%	56.07%	52.98%	63.84%	57.59%	58.33%	58.74%
Earnings before Interest and Taxes (EBIT)	1,458	3,630	3,668	4,604	713	1,743	1,972	1,385
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	6,273	8,635	8,470	9,664	6,159	3,967	3,685	2,925
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.64	0.79	0.75	0.90	0.80	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.83	0.91	0.84	0.98	0.74	0.00	0.00	0.00
Price to Earnings (P/E)	24.70	11.50	13.01	8.37	55.02	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	4.58%	5.72%	2.25%	0.00%	0.00%
Earnings Yield	4.05%	8.70%	7.69%	11.95%	1.82%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.82	0.90	0.89	0.96	0.92	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.17	2.20	2.20	2.55	2.57	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	9.76	7.72	7.65	7.63	12.83	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	42.00	18.35	17.66	16.02	110.79	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	15.84	21.33	22.44	15.60	120.46	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	12.93	9.05	7.00	8.07	12.64	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	16.93	33.60	9.47	5.47	12.26	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.67	0.69	0.76	0.90	1.08	1.11	0.49	0.00
Long-Term Debt to Equity	0.62	0.64	0.73	0.89	0.95	0.92	0.49	0.00
Financial Leverage	0.54	0.55	0.60	0.79	0.95	0.77	0.30	0.00
Leverage Ratio	2.14	2.26	2.41	2.60	2.69	2.48	2.04	0.00
Compound Leverage Factor	0.51	1.76	1.63	1.87	-2.13	1.63	2.11	0.00
Debt to Total Capital	39.97%	40.82%	43.33%	47.24%	51.86%	52.58%	32.82%	0.00%
Short-Term Debt to Total Capital	3.03%	3.16%	2.03%	0.23%	5.98%	9.01%	0.00%	0.00%
Long-Term Debt to Total Capital	36.94%	37.65%	41.29%	47.01%	45.89%	43.58%	32.82%	0.00%
Preferred Equity to Total Capital	14.42%	16.10%	17.04%	17.21%	17.11%	15.09%	3.02%	0.00%
Noncontrolling Interests to Total Capital	0.01%	0.01%	0.01%	0.04%	0.04%	0.04%	0.67%	0.00%
Common Equity to Total Capital	45.60%	43.08%	39.63%	35.51%	30.99%	32.29%	63.49%	0.00%
Debt to EBITDA	5.11	3.82	4.22	4.34	7.72	13.02	2.52	0.00
Net Debt to EBITDA	4.17	3.03	3.08	3.11	6.59	11.18	1.49	0.00
Long-Term Debt to EBITDA	4.72	3.53	4.03	4.32	6.83	10.79	2.52	0.00
Debt to NOPAT	8.28	10.57	12.40	8.86	72.47	22.86	4.74	0.00
Net Debt to NOPAT	6.76	8.37	9.03	6.35	61.87	19.64	2.81	0.00
Long-Term Debt to NOPAT	7.66	9.75	11.81	8.82	64.12	18.94	4.74	0.00
Altman Z-Score	0.75	0.84	0.82	0.87	0.63	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	25.62%	28.63%	31.38%	34.12%	33.71%	24.25%	5.49%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	1.11	0.97	1.21	1.53	1.13	1.17	1.46	0.00
Quick Ratio	0.49	0.48	0.72	0.99	0.64	0.57	0.97	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	3,617	1,983	6,839	13,493	6,442	-64,365	-22,791	0.00
Operating Cash Flow to CapEx	151.73%	154.44%	609.65%	532.03%	326.50%	-393.87%	301.57%	238.91%
Free Cash Flow to Firm to Interest Expense	2.49	1.55	4.99	6.00	4.18	-86.05	-75.87	0.00
Operating Cash Flow to Interest Expense	3.26	5.76	6.74	4.07	4.06	-3.94	11.83	11.24
Operating Cash Flow Less CapEx to Interest Expense	1.11	2.03	5.64	3.30	2.82	-4.95	7.91	6.54
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.28	0.28	0.26	0.24	0.25	0.23	0.43	0.00
Accounts Receivable Turnover	6.06	5.71	4.59	4.09	4.47	3.55	4.21	0.00
Inventory Turnover	1.21	1.29	1.30	1.16	0.96	0.80	2.29	0.00
Fixed Asset Turnover	2.18	2.35	2.25	2.22	2.47	2.21	3.30	0.00
Accounts Payable Turnover	2.22	2.05	2.48	2.96	3.44	2.25	2.06	0.00
Days Sales Outstanding (DSO)	60.27	63.94	79.58	89.29	81.57	102.87	86.64	0.00
Days Inventory Outstanding (DIO)	301.92	283.76	280.88	315.89	380.63	458.16	159.67	0.00
Days Payable Outstanding (DPO)	164.64	178.03	147.37	123.51	106.16	162.16	176.83	0.00
Cash Conversion Cycle (CCC)	197.56	169.66	213.09	281.66	356.04	398.87	69.47	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	74,258	74,008	72,868	76,821	85,585	91,371	24,747	0.00
Invested Capital Turnover	0.38	0.41	0.39	0.36	0.35	0.32	1.35	0.00
Increase / (Decrease) in Invested Capital	250	1,140	-3,953	-8,764	-5,787	66,625	24,747	0.00
Enterprise Value (EV)	61,249	66,624	64,780	73,765	79,009	0.00	0.00	0.00
Market Capitalization	23,532	27,457	24,637	28,445	22,715	0.00	0.00	0.00
Book Value per Share	$21.57	$20.91	$19.02	$20.22	$18.15	$20.27	$0.00	$0.00
Tangible Book Value per Share	($16.23)	($20.05)	($20.35)	($25.87)	($30.65)	($31.33)	$0.00	$0.00
Total Capital	80,133	80,881	82,583	88,704	91,643	98,224	28,255	0.00
Total Debt	32,031	33,012	35,782	41,903	47,528	51,649	9,274	0.00
Total Long-Term Debt	29,603	30,454	34,103	41,703	42,052	42,803	9,274	0.00
Net Debt	26,156	26,139	26,067	30,020	40,577	44,372	5,487	0.00
Capital Expenditures (CapEx)	3,122	4,766	1,517	1,718	1,914	749	1,179	982
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,025	-2,094	-1,629	-39	2,265	6,492	440	0.00
Debt-free Net Working Capital (DFNWC)	4,052	1,926	5,368	8,695	8,215	12,797	3,211	0.00
Net Working Capital (NWC)	1,623	-633	3,688	8,495	2,739	3,952	3,211	0.00
Net Nonoperating Expense (NNE)	2,913	735	991	1,328	243	1,046	199	91
Net Nonoperating Obligations (NNO)	26,156	26,139	26,067	30,020	41,470	44,796	5,766	0.00
Total Depreciation and Amortization (D&A)	4,814	5,005	4,802	5,059	5,446	2,225	1,714	1,539
Debt-free, Cash-free Net Working Capital to Revenue	3.63%	-6.90%	-5.54%	-0.14%	7.38%	34.47%	2.64%	0.00%
Debt-free Net Working Capital to Revenue	14.37%	6.35%	18.27%	30.08%	26.75%	67.94%	19.28%	0.00%
Net Working Capital to Revenue	5.76%	-2.09%	12.55%	29.39%	8.92%	20.98%	19.28%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.61	$204.29	$147.14	$240.72	$28.41	$113.50	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	1.69B	1.69B	1.67B	1.72B	1.56B	1.57B	0.00	0.00
Adjusted Diluted Earnings per Share	$0.60	$201.94	$145.87	$238.96	$28.25	$112.86	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	1.69B	1.69B	1.67B	1.72B	1.56B	1.57B	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.69B	1.69B	1.67B	1.72B	1.56B	1.57B	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	1,947	4,048	3,883	4,861	2,280	2,143	2,979	1,655
Normalized NOPAT Margin	6.91%	13.34%	13.21%	16.82%	7.43%	11.38%	17.88%	10.64%
Pre Tax Income Margin	1.24%	9.31%	8.48%	11.45%	-1.85%	6.08%	12.27%	8.28%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.00	2.84	2.67	2.05	0.46	2.33	6.56	6.64
NOPAT to Interest Expense	2.66	2.44	2.10	2.10	0.43	3.02	6.51	5.40
EBIT Less CapEx to Interest Expense	-1.14	-0.89	1.57	1.28	-0.78	1.33	2.64	1.93
NOPAT Less CapEx to Interest Expense	0.51	-1.29	1.00	1.34	-0.82	2.02	2.59	0.70
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	199.16%	88.13%	123.24%	75.33%	638.03%	105.83%	76.00%	122.66%
Augmented Payout Ratio	200.78%	96.63%	156.93%	85.15%	646.46%	105.83%	86.04%	142.67%

No quarterly metrics and ratios for Takeda Pharmaceutical are available.

Frequently Asked Questions About Takeda Pharmaceutical's Financials

When does Takeda Pharmaceutical's fiscal year end?

According to the most recent income statement we have on file, Takeda Pharmaceutical's financial year ends in March. Their financial year 2024 ended on March 31, 2024.

How has Takeda Pharmaceutical's net income changed over the last 7 years?

Takeda Pharmaceutical's net income appears to be on an upward trend, with a most recent value of $953.56 million in 2024, falling from $1.04 billion in 2017. The previous period was $2.39 billion in 2023. See Takeda Pharmaceutical's forecast for analyst expectations on what’s next for the company.

What is Takeda Pharmaceutical's operating income?

Takeda Pharmaceutical's total operating income in 2024 was $1.42 billion, based on the following breakdown:

Total Gross Profit: $18.76 billion
Total Operating Expenses: $17.35 billion

How has Takeda Pharmaceutical revenue changed over the last 7 years?

Over the last 7 years, Takeda Pharmaceutical's total revenue changed from $15.55 billion in 2017 to $28.20 billion in 2024, a change of 81.3%.

How much debt does Takeda Pharmaceutical have?

Takeda Pharmaceutical's total liabilities were at $51.81 billion at the end of 2024, a 9.5% decrease from 2023, and a 163.6% increase since 2018.

How much cash does Takeda Pharmaceutical have?

In the past 6 years, Takeda Pharmaceutical's cash and equivalents has ranged from $2.77 billion in 2018 to $8.73 billion in 2021, and is currently $3.03 billion as of their latest financial filing in 2024.

How has Takeda Pharmaceutical's book value per share changed over the last 7 years?

Over the last 7 years, Takeda Pharmaceutical's book value per share changed from 0.00 in 2017 to 21.57 in 2024, a change of 2,156.9%.

Related Companies

This page (NYSE:TAK) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Financials

Frequently Asked Questions About Takeda Pharmaceutical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Takeda Pharmaceutical (TAK) Financials

Annual Income Statements for Takeda Pharmaceutical

Quarterly Income Statements for Takeda Pharmaceutical

Annual Cash Flow Statements for Takeda Pharmaceutical

Quarterly Cash Flow Statements for Takeda Pharmaceutical

Annual Balance Sheets for Takeda Pharmaceutical

Quarterly Balance Sheets for Takeda Pharmaceutical

Annual Metrics And Ratios for Takeda Pharmaceutical

Quarterly Metrics And Ratios for Takeda Pharmaceutical

Frequently Asked Questions About Takeda Pharmaceutical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools